Halozyme Therapeutics, Inc. (HALO) — Analyst outlook / Analyst consensus target is. Based on 27 analyst ratings, the consensus is bullish — 17 Buy, 9 Hold, 1 Sell.
The consensus price target is $73.83 (low: $56.00, high: $94.00), representing an upside of 9.7% from the current price $67.31.
Analysts estimate Earnings Per Share (EPS) of $4.13 and revenue of $1.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $3.50 vs est $4.13 (missed -15.2%). 2025: actual $2.64 vs est $6.55 (missed -59.7%). Analyst accuracy: 17%.
HALO Stock — 12-Month Price Forecast
$73.83
▲ +9.69% Upside
Average Price Target
Based on 27 Wall Street analysts offering 12-month price targets for Halozyme Therapeutics, Inc., the average price target is $73.83, with a high forecast of $94.00, and a low forecast of $56.00.
The average price target represents a +9.69% change from the last price of $67.31.
Highest Price Target
$94.00
Average Price Target
$73.83
Lowest Price Target
$56.00
HALO Analyst Ratings
Buy
Based on 27 analysts giving stock ratings to Halozyme Therapeutics, Inc. in the past 3 months
EPS Estimates — HALO
17%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual $3.50
vs Est $4.13
▼ 18.0% off
2025
Actual $2.64
vs Est $6.55
▼ 148.3% off
Profitability Outlook
Company is profitable with solid earnings. EPS trend is declining. Analysts forecast meaningful EPS growth ahead.
Revenue Estimates — HALO
99%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $1.015B
vs Est $1.003B
▲ 1.2% off
2025
Actual $1.397B
vs Est $1.394B
▲ 0.2% off
Revenue Trend
Moderate revenue growth trend. Analysts forecast revenue contraction ahead.
